Grifols, S.A. (NASDAQ:GRFS) is a company that unfortunately has not been performing as I expected it to. My position is in the green, but this has more to do with FX and me adding shares below my ...

Wolfspeed bankruptcy watch, North Carolina lands more data centers, Duke University’s funding crunch, and an AI companion named Frank. But first, NC high schools rethink career readiness.

I have been covering Grifols (NASDAQ:GRFS) for some time now, through the potential of a sale of the entire company, and back again when that sale did not materialize. I view this as a very good ...

Below, we take a look at Grifols (GRFS), which currently has a Momentum Style Score of A. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings ...

(Bloomberg) -- Grifols SA, the Spanish pharmaceutical company hit by a short seller attack this year, said it overstated the value of its stake in a Chinese firm and reported an accounting ...

Grifols (NASDAQ:GRFS) announced Friday that its board of directors unanimously adopted a series of measures to facilitate a possible go-private transaction involving its founding family and asset ...

Spanish plasma-derived medicines specialist Grifols (MCE: GRF) announced that the positive Phase III study data on its fibrinogen concentrate, BT524, has been published in eClinicalMedicine, a ...

Grifols (GRFS) said: “Grifols remains focused on the continued execution of its strategic plan and reaffirms its guidance for FY2025.Due to the impact of the Inflation Reduction Act on its ...

Grifols GRF-0.39%decrease; red down pointing triangle said it plans to outline its strategy as a standalone company after Brookfield Asset Management dropped out of talks for a 6.45 billion-euro ...

The Grifols family has held "very preliminary talks" through several investment firms over a potential takeover bid, according to a source close to the pharmaceutical company's reference shareholders.